leisure time -WSS

leisure time

author：leisure time 2025-09-29 13:30:36 - browse：35

Adam's take main illustration — Molly Ferguson/STAT

Cassava Sciences has long claimed its experimental drug, called simufilam, slows the cognitive decline of people with Alzheimer’s. On Friday, we learned how: The company recruited a large number of people into its clinical trial who don’t have Alzheimer’s.

People who almost certainly had Alzheimer’s were also included in the study, but in this group, a placebo outperformed Cassava’s drug.

The conclusion, of course, is obvious: Simufilam is inactive. It’s an inert compound no more effective than a placebo. Cassava’s assertion that simufilam is showing “disease-modifying activity” falls apart given its study was opened to people who should have been ineligible because they were misdiagnosed with Alzheimer’s. Whether that was done intentionally or unwittingly isn’t known, but it’s certainly troubling and makes the case for immediate, regulatory intervention even stronger.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： OTC birth control: A brief history of over the counter pill design

explore

WSS

2 US Navy sailors arrested for allegedly spying for China

TytoCare raises $49 million to build out AI

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

A cyberattack has disrupted hospitals and health care in several states

White House drug shortage group privately met with industry

hotspot

leisure time

focus

Medical leaders decry Supreme Court decision on affirmative action

White House drug shortage group privately met with industry

How to save PrEP access — and even expand it

'Ancient DNA,' 23andMe reveal African American ancestries

Drug repurposing or repositioning? The language matters

ASCO: Palliative care found as helpful given virtually as in person

Drug repurposing or repositioning? The language matters

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

HIV drugs protect against transmission, even in unprotected sex

focus

NIH documents show early flaws of $1.6 billion long Covid program

Nearly two

My superpower is killing ticks

What Mike Pence has said that could be used in a Donald Trump trial

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

HIV drugs protect against transmission, even in unprotected sex

entertainment

hotspot

explore

explore